Furthermore, in the sub-study of COACH [13] galectin-3 was shown to be a robust independent marker of cardiovascular mid-term (18-month) outcomes in HF patients with a much stronger relevance in patients with preserved left ventricular ejection fraction (LVEF). Here, LGALS3 is linked to hydrops fetalis.